ReviewDepression and anxiety2026
Integrative Management of Premenstrual Dysphoric Disorder: The Role of Traditional Chinese Medicine.
Review in Depression and anxiety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS), affecting 3%-8% of women of reproductive age. It is characterized by emotional, behavioral, and physical symptoms during the luteal phase, primarily driven by neuroendocrine sensitivity to hormonal fluctuations and dysregulation of central neurotransmitter systems. Genetic predisposition and environmental stressors contribute to its onset. Although conventional treatments such as selective serotonin reuptake inhibitors (SSRIs) and hormonal therapies offer symptom relief, they are often accompanied by adverse effects and limited long-term efficacy. Traditional Chinese medicine (TCM) posits that the core pathogenesis of PMDD lies in the dysfunction of liver's conveyance and dispersion, which may consistent with modern biological research evidence. TCM approaches, represented by Chinese herbal medicine and acupuncture, may alleviate symptoms of PMDD by targeting and modulating its core modern pathogenic mechanisms. With its few side effects and the unique advantage of individualized treatment based on syndrome differentiation, TCM holds the potential to become a mainstream therapeutic option for PMDD. This narrative review synthesizes evidence from clinical trials, animal and pharmacological studies to explore the efficacy and underlying mechanisms of TCM in the treatment of PMDD and compares these approaches with conventional therapies. Nonetheless, the integration of TCM into mainstream practice for PMDD is still hampered by challenges such as insufficient evidence-based medical data. Research in TCM focusing on biomarker identification, establishment of standardized treatment protocols, and refinement of efficacy evaluation systems is expected to drive its evolution into a mainstream treatment option for PMDD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.